Patients with colon cancer who consumed an anti-inflammatory diet during a Phase III clinical trial showed longer overall survival post-treatment compared to those on a proinflammatory diet, according to analysis. Engaging in higher levels of physical activity may amplify the positive influence on survival. The median 5-year survival for patients with stage III colon cancer is around 80%. The CALGB/SWOG 80702 (Alliance) trial was initiated in 2010 to reduce the risk of cancer recurrence. Patients in the trial were treated with surgery followed by either three or six months of chemotherapy, with or without celecoxib, an anti-inflammatory drug. Of 2,526...